The importance of the endothelium in atherothrombosis and coronary stenting

Nature Reviews Cardiology

Volumn 9, Issue 8, 2012, Pages 439-453

  Otsuka, Fumiyuki ^a   Finn, Aloke V ^b   Yazdani, Saami K ^a   Nakano, Masataka ^a   Kolodgie, Frank D ^a   Virmani, Renu ^a  

^a CVPATH INSTITUTE   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; CD31 ANTIGEN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EVEROLIMUS; INTEGRIN; NITRIC OXIDE; PACLITAXEL; PROSTACYCLIN; PROTEIN; RAPAMYCIN; TISSUE FACTOR PATHWAY INHIBITOR; TORC1 PROTEIN; TORC2 PROTEIN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ARTERY INJURY; ATHEROSCLEROSIS; BARE METAL STENT; CELL JUNCTION; CELL REGENERATION; CORONARY STENT; DRUG ELUTING STENT; DRUG SAFETY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; HUMAN; NONHUMAN; OPTICAL COHERENCE TOMOGRAPHY; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PERMEABILITY; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SHEAR STRESS; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOGENICITY; THROMBOSIS; VASCULAR ENDOTHELIUM; VASODILATATION;

CORONARY RESTENOSIS; CORONARY THROMBOSIS; DRUG-ELUTING STENTS; ENDOTHELIUM, VASCULAR; FIBRINOLYTIC AGENTS; HEMODYNAMICS; HUMANS; NITRIC OXIDE; OXIDATIVE STRESS; RISK FACTORS; TIME FACTORS;

EID: 84864276715     PISSN: 17595002     EISSN: 17595010     Source Type: Journal    
DOI: 10.1038/nrcardio.2012.64     Document Type: Review

References (123)

1. Serruys, P. W., Kutryk, M. J. & Ong, A. T. Coronary-artery stents. N. Engl. J. Med. 354, 483-495 (2006). (Pubitemid 43200299)
2. Morice, M. C. et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N. Engl. J. Med. 346, 1773-1780 (2002).
3. Ryan, J., Linde-Zwirble, W., Engelhart, L., Cooper, L. & Cohen, D. J. Temporal changes in coronary revascularization procedures, outcomes, and costs in the bare-metal stent and drug-eluting stent eras: results from the US Medicare program. Circulation 119, 952-961 (2009).
4. Stone, G. W. et al. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N. Engl. J. Med. 350, 221-231 (2004). (Pubitemid 38067635)
5. Lagerqvist, B. et al. Stent thrombosis in Sweden: a report from the Swedish Coronary Angiography and Angioplasty Registry. Circ. Cardiovasc. Interv. 2, 401-408 (2009).
6. Joner, M. et al. Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J. Am. Coll. Cardiol. 48, 193-202 (2006). (Pubitemid 43929240)
7. Finn, A. V. et al. Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization. Circulation 115, 2435-2441 (2007). (Pubitemid 46717966)
8. Leon, M. B. et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (randomized comparison of zotarolimus-and paclitaxel-eluting stents in patients with coronary artery disease) trial. JACC Cardiovasc. Interv. 3, 1043-1050 (2010).
9. Baber, U. et al. Impact of the everolimus-eluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J. Am. Coll. Cardiol. 58, 1569-1577 (2011).
10. de la Torre Hernandez, J. M. et al. Thrombosis of second-generation drug-eluting stents in real practice results from the multicenter Spanish registry ESTROFA-2 (Estudio Español Sobre Trombosis de Stents Farmacoactivos de Segunda Generacion-2). JACC Cardiovasc. Interv. 3, 911-919 (2010).
11. Stefanini, G. G. et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 378, 1940-1948 (2011).
12. Mehta, D. & Malik, A. B. Signaling mechanisms regulating endothelial permeability. Physiol. Rev. 86, 279-367 (2006).
13. Frank, P. G., Pavlides, S. & Lisanti, M. P. Caveolae and transcytosis in endothelial cells: role in atherosclerosis. Cell Tissue Res. 335, 41-47 (2009).
14. Simionescu, M. & Antohe, F. Functional ultrastructure of the vascular endothelium: changes in various pathologies. Handb. Exp. Pharmacol. 176, 41-69 (2006).
15. Jimenez, J. M. & Davies, P. F. Hemodynamically driven stent strut design. Ann. Biomed. Eng. 37, 1483-1494 (2009).
16. Xu, J. & Zou, M. H. Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Circulation 120, 1266-1286 (2009).
17. Wu, K. K. & Thiagarajan, P. Role of endothelium in thrombosis and hemostasis. Annu. Rev. Med. 47, 315-331 (1996). (Pubitemid 26138894)
18. Kwaan, H. C. & Samama, M. M. The significance of endothelial heterogeneity in thrombosis and hemostasis. Semin. Thromb. Hemost. 36, 286-300 (2010).
19. Rogers, C., Tseng, D. Y., Squire, J. C. & Edelman, E. R. Balloon-artery interactions during stent placement: a finite element analysis approach to pressure, compliance, and stent design as contributors to vascular injury. Circ. Res. 84, 378-383 (1999). (Pubitemid 29120002)
20. Dejana, E., Orsenigo, F., Molendini, C., Baluk, P. & McDonald, D. M. Organization and signaling of endothelial cell-to-cell junctions in various regions of the blood and lymphatic vascular trees. Cell Tissue Res. 335, 17-25 (2009).
21. Dejana, E., Tournier-Lasserve, E. & Weinstein, B. M. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev. Cell 16, 209-221 (2009).
22. Furuse, M. et al. Occludin: a novel integral membrane protein localizing at tight junctions. J. Cell Biol. 123, 1777-1788 (1993). (Pubitemid 24012933)
23. Nitta, T. et al. Size-selective loosening of the blood-brain barrier in claudin-5-deficient mice. J. Cell Biol. 161, 653-660 (2003). (Pubitemid 36578587)
24. Imhof, B. A. & Aurrand-Lions, M. Adhesion mechanisms regulating the migration of monocytes. Nat. Rev. Immunol. 4, 432-444 (2004). (Pubitemid 38745555)
25. Vestweber, D. Lymphocyte trafficking through blood and lymphatic vessels: more than just selectins, chemokines and integrins. Eur. J. Immunol. 33, 1361-1364 (2003). (Pubitemid 36609154)
26. Lampugnani, M. G. & Dejana, E. Interendothelial junctions: structure, signalling and functional roles. Curr. Opin. Cell Biol. 9, 674-682 (1997). (Pubitemid 27424924)
27. Goodenough, D. A. & Paul, D. L. Beyond the gap: functions of unpaired connexon channels. Nat. Rev. Mol. Cell Biol. 4, 285-294 (2003). (Pubitemid 36383955)
28. Muller, W. A., Weigl, S. A., Deng, X. & Phillips, D. M. PECAM-1 is required for transendothelial migration of leukocytes. J. Exp. Med. 178, 449-460 (1993). (Pubitemid 23218193)
29. Newman, P. J. et al. PECAM-1 (CD31) cloning and relation to adhesion molecules of the immunoglobulin gene superfamily. Science 247, 1219-1222 (1990).
30. Sanderson, M. J., Charles, A. C., Boitano, S. & Dirksen, E. R. Mechanisms and function of intercellular calcium signaling. Mol. Cell Endocrinol. 98, 173-187 (1994). (Pubitemid 24029403)
31. Bazzoni, G. & Dejana, E. Endothelial cell-to-cell junctions: molecular organization and role in vascular homeostasis. Physiol. Rev. 84, 869-901 (2004). (Pubitemid 38823769)
32. Gonzalez-Mariscal, L., Tapia, R. & Chamorro, D. Crosstalk of tight junction components with signaling pathways. Biochim. Biophys. Acta 1778, 729-756 (2008). (Pubitemid 351317800)
33. Traweger, A. et al. Nuclear Zonula occludens-2 alters gene expression and junctional stability in epithelial and endothelial cells. Differentiation 76, 99-106 (2008).
34. Lampugnani, M. G., Orsenigo, F., Gagliani, M. C., Tacchetti, C. & Dejana, E. Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments. J. Cell Biol. 174, 593-604 (2006). (Pubitemid 44231870)
35. Rudini, N. et al. VE-cadherin is a critical endothelial regulator of TGF-beta signalling. EMBO J. 27, 993-1004 (2008). (Pubitemid 351508155)
36. Cheng, Y. F. & Kramer, R. H. Human microvascular endothelial cells express integrin-related complexes that mediate adhesion to the extracellular matrix. J. Cell Physiol. 139, 275-286 (1989). (Pubitemid 19126767)
37. Burridge, K., Fath, K., Kelly, T., Nuckolls, G. & Turner, C. Focal adhesions: transmembrane junctions between the extracellular matrix and the cytoskeleton. Annu. Rev. Cell Biol. 4, 487-525 (1988). (Pubitemid 19139264)
38. Vane, J. R., Anggard, E. E. & Botting, R. M. Regulatory functions of the vascular endothelium. N. Engl. J. Med. 323, 27-36 (1990). (Pubitemid 20209469)
39. Napoli, C. et al. Nitric oxide and atherosclerosis: an update. Nitric Oxide 15, 265-279 (2006). (Pubitemid 44649284)
40. Vanhoutte, P. M. Endothelial dysfunction: the first step toward coronary arteriosclerosis. Circ. J. 73, 595-601 (2009).
41. Wang, G. R., Zhu, Y., Halushka, P. V., Lincoln, T. M. & Mendelsohn, M. E. Mechanism of platelet inhibition by nitric oxide: in vivo phosphorylation of thromboxane receptor by cyclic GMP-dependent protein kinase. Proc. Natl Acad. Sci. USA 95, 4888-4893 (1998). (Pubitemid 28208520)
42. Macdonald, P. S., Read, M. A. & Dusting, G. J. Synergistic inhibition of platelet aggregation by endothelium-derived relaxing factor and prostacyclin. Thromb. Res. 49, 437-449 (1988).
43. Radomski, M. W., Palmer, R. M. & Moncada, S. The role of nitric oxide and cGMP in platelet adhesion to vascular endothelium. Biochem. Biophys. Res. Commun. 148, 1482-1489 (1987). (Pubitemid 18074679)
44. Busse, R. et al. EDHF: bringing the concepts together. Trends Pharmacol. Sci. 23, 374-380 (2002).
45. Smith, D., Gilbert, M. & Owen, W. G. Tissue plasminogen activator release in vivo in response to vasoactive agents. Blood 66, 835-839 (1985). (Pubitemid 15242467)
46. Bauer, K. A., Kass, B. L., Beeler, D. L. & Rosenberg, R. D. Detection of protein C activation in humans. J. Clin. Invest. 74, 2033-2041 (1984). (Pubitemid 15197346)
47. Nawroth, P., Kisiel, W. & Stern, D. The role of endothelium in the homeostatic balance of haemostasis. Clin. Haematol. 14, 531-546 (1985). (Pubitemid 15038463)
48. Girard, T. J. et al. Functional significance of the kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 518-520 (1989). (Pubitemid 19107996)
49. Jones, K. L. et al. Platelet endothelial cell adhesion molecule-1 is a negative regulator of platelet-collagen interactions. Blood 98, 1456-1463 (2001).
50. Falati, S. et al. Platelet PECAM-1 inhibits thrombus formation in vivo. Blood 107, 535-541 (2006). (Pubitemid 43076376)
51. Simionescu, M., Popov, D. & Sima, A. Endothelial transcytosis in health and disease. Cell Tissue Res. 335, 27-40 (2009).
52. Ross, R. Atherosclerosis-an inflammatory disease. N. Engl. J. Med. 340, 115-126 (1999).
53. Brunner, H. et al. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the working group on endothelins and endothelial factors of the European Society of Hypertension. J. Hypertens. 23, 233-246 (2005). (Pubitemid 40279622)
54. Cai, H. NAD(P)H oxidase-dependent self-propagation of hydrogen peroxide and vascular disease. Circ. Res. 96, 818-822 (2005). (Pubitemid 40604964)
55. Stabler, T., Kenjale, A., Ham, K., Jelesoff, N. & Allen, J. Potential mechanisms for reduced delivery of nitric oxide to peripheral tissues in diabetes mellitus. Ann. NY Acad. Sci. 1203, 101-106 (2010).
56. Milsom, A. B. et al. Abnormal metabolic fate of nitric oxide in type I diabetes mellitus. Diabetologia 45, 1515-1522 (2002).
57. Bunn, H. F. & Briehl, R. W. The interaction of 2, 3-diphosphoglycerate with various human hemoglobins. J. Clin. Invest. 49, 1088-1095 (1970).
58. Tai, S. C., Robb, G. B. & Marsden, P. A. Endothelial nitric oxide synthase: a new paradigm for gene regulation in the injured blood vessel. Arterioscler. Thromb. Vasc. Biol. 24, 405-412 (2004). (Pubitemid 38326131)
59. Sima, A. V., Stancu, C. S. & Simionescu, M. Vascular endothelium in atherosclerosis. Cell Tissue Res. 335, 191-203 (2009).
60. Schmidt, T. S. & Alp, N. J. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin. Sci. (Lond.) 113, 47-63 (2007). (Pubitemid 47066025)
61. Civelek, M., Manduchi, E., Riley, R. J., Stoeckert, C. J. Jr & Davies, P. F. Coronary artery endothelial transcriptome in vivo: identification of endoplasmic reticulum stress and enhanced reactive oxygen species by gene connectivity network analysis. Circ. Cardiovasc. Genet. 4, 243-252 (2011).
62. Simionescu, M. Implications of early structural-functional changes in the endothelium for vascular disease. Arterioscler. Thromb. Vasc. Biol. 27, 266-274 (2007). (Pubitemid 46143039)
63. Mehrabi, M. R. et al. Accumulation of oxidized LDL in human semilunar valves correlates with coronary atherosclerosis. Cardiovasc. Res. 45, 874-882 (2000). (Pubitemid 30089649)
64. Williams, K. J. & Tabas, I. Lipoprotein retention-and clues for atheroma regression. Arterioscler. Thromb. Vasc. Biol. 25, 1536-1540 (2005). (Pubitemid 41098918)
65. Lum, H. & Malik, A. B. Regulation of vascular endothelial barrier function. Am. J. Physiol. 267, L223-L241 (1994).
66. Dudek, S. M. & Garcia, J. G. Cytoskeletal regulation of pulmonary vascular permeability. J. Appl. Physiol. 91, 1487-1500 (2001). (Pubitemid 32900340)
67. Libby, P. Inflammation in atherosclerosis. Nature 420, 868-874 (2002). (Pubitemid 36019640)
68. Kipshidze, N. et al. Role of the endothelium in modulating neointimal formation: vasculoprotective approaches to attenuate restenosis after percutaneous coronary interventions. J. Am. Coll. Cardiol. 44, 733-739 (2004). (Pubitemid 39099565)
69. van Beusekom, H. M. et al. Long-term endothelial dysfunction is more pronounced after stenting than after balloon angioplasty in porcine coronary arteries. J. Am. Coll. Cardiol. 32, 1109-1117 (1998). (Pubitemid 28459607)
70. Wenaweser, P. et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J. Am. Coll. Cardiol. 52, 1134-1140 (2008).
71. Stone, G. W. et al. Safety and efficacy of sirolimus-and paclitaxel-eluting coronary stents. N. Engl. J. Med. 356, 998-1008 (2007). (Pubitemid 46376800)
72. Kastrati, A. et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N. Engl. J. Med. 356, 1030-1039 (2007). (Pubitemid 46376803)
73. Kolandaivelu, K. et al. Stent thrombogenicity early in high-risk interventional settings is driven by stent design and deployment and protected by polymer-drug coatings. Circulation 123, 1400-1409 (2011).
74. Nakazawa, G. et al. Coronary responses and differential mechanisms of late stent thrombosis attributed to first-generation sirolimus-and paclitaxel-eluting stents. J. Am. Coll. Cardiol. 57, 390-398 (2011).
75. Nakazawa, G. et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: an autopsy study. Circulation 118, 1138-1145 (2008).
76. Finn, A. V. et al. Differential response of delayed healing and persistent inflammation at sites of overlapping sirolimus-or paclitaxel-eluting stents. Circulation 112, 270-278 (2005). (Pubitemid 40982311)
77. Nakazawa, G. et al. Pathological findings at bifurcation lesions: the impact of flow distribution on atherosclerosis and arterial healing after stent implantation. J. Am. Coll. Cardiol. 55, 1679-1687 (2010).
78. Nakazawa, G. et al. Incidence and predictors of drug-eluting stent fracture in human coronary artery a pathologic analysis. J. Am. Coll. Cardiol. 54, 1924-1931 (2009).
79. Asahara, T. et al. Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ. Res. 85, 221-228 (1999). (Pubitemid 29377293)
80. Joner, M. et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J. Am. Coll. Cardiol. 52, 333-342 (2008). (Pubitemid 352001347)
81. Nakazawa, G. et al. Evaluation of polymer-based comparator drug-eluting stents using a rabbit model of iliac artery atherosclerosis. Circ. Cardiovasc. Interv. 4, 38-46 (2011).
82. Virmani, R., Kolodgie, F. D., Farb, A. & Lafont, A. Drug eluting stents: are human and animal studies comparable? Heart 89, 133-138 (2003). (Pubitemid 36115090)
83. Liu, L. et al. Rapamycin inhibits cell motility by suppression of mTOR-mediated S6K1 and 4E-BP1 pathways. Oncogene 25, 7029-7040 (2006). (Pubitemid 44722071)
84. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005). (Pubitemid 40262113)
85. Tsurumi, Y. et al. Reciprocal relation between VEGF and NO in the regulation of endothelial integrity. Nat. Med. 3, 879-886 (1997). (Pubitemid 27353448)
86. Vinals, F., Chambard, J. C. & Pouyssegur, J. p70 S6 kinase-mediated protein synthesis is a critical step for vascular endothelial cell proliferation. J. Biol. Chem. 274, 26776-26782 (1999).
87. Morales-Ruiz, M. et al. Vascular endothelial growth factor-stimulated actin reorganization and migration of endothelial cells is regulated via the serine/threonine kinase Akt. Circ. Res. 86, 892-896 (2000). (Pubitemid 30246987)
88. Fosbrink, M., Niculescu, F., Rus, V., Shin, M. L. & Rus, H. C5b-9-induced endothelial cell proliferation and migration are dependent on Akt inactivation of forkhead transcription factor FOXO1. J. Biol. Chem. 281, 19009-19018 (2006). (Pubitemid 44035404)
89. Fulton, D. et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature 399, 597-601 (1999).
90. Shin, I. et al. PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat. Med. 8, 1145-1152 (2002). (Pubitemid 35175970)
91. Fleming, I. & Busse, R. Molecular mechanisms involved in the regulation of the endothelial nitric oxide synthase. Am. J. Physiol. Regul. Integr. Comp. Physiol. 284, R1-R12 (2003). (Pubitemid 36008649)
92. Yamamoto, K. & Ando, J. New molecular mechanisms for cardiovascular disease: blood flow sensing mechanism in vascular endothelial cells. J. Pharmacol. Sci. 116, 323-331 (2011).
93. Togni, M. et al. Sirolimus-eluting stents associated with paradoxic coronary vasoconstriction. J. Am. Coll. Cardiol. 46, 231-236 (2005). (Pubitemid 40966848)
94. Hofma, S. H. et al. Indication of long-term endothelial dysfunction after sirolimus-eluting stent implantation. Eur. Heart J. 27, 166-170 (2006). (Pubitemid 43069032)
95. Hamilos, M. et al. Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ. Cardiovasc. Interv. 1, 193-200 (2008).
96. van den Heuvel, M. et al. Specific coronary drug-eluting stents interfere with distal microvascular function after single stent implantation in pigs. JACC Cardiovasc. Interv. 3, 723-730 (2010).
97. Pendyala, L. K. et al. The first-generation drug-eluting stents and coronary endothelial dysfunction. JACC Cardiovasc. Interv. 2, 1169-1177 (2009).
98. Sahler, L. G. et al. Comparison of vasa vasorum after intravascular stent placement with sirolimis drug-eluting and bare metal stents. J. Med. Imaging Radiat. Oncol. 52, 570-575 (2008).
99. van Beusekom, H. M. et al. Endothelial function rather than endothelial restoration is altered in paclitaxel-as compared to bare metal-, sirolimus and tacrolimus-eluting stents. EuroIntervention 6, 117-125 (2010).
100. Kim, J. W. et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus-versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction. J. Am. Coll. Cardiol. 53, 1653-1659 (2009).
101. Shin, D. I. et al. Long-term coronary endothelial function after zotarolimus-eluting stent implantation. A 9 month comparison between zotarolimus-eluting and sirolimus-eluting stents. Int. Heart J. 49, 639-652 (2008).
102. Lowe, H. C., Narula, J., Fujimoto, J. G. & Jang, I. K. Intracoronary optical diagnostics current status, limitations, and potential. JACC Cardiovasc. Interv. 4, 1257-1270 (2011).
103. Fujii, K. et al. Endothelium-dependent coronary vasomotor response and neointimal coverage of zotarolimus-eluting stents 3 months after implantation. Heart 97, 977-982 (2011).
104. Liu, L. et al. Imaging the subcellular structure of human coronary atherosclerosis using micro-optical coherence tomography. Nat. Med. 17, 1010-1014 (2011).
105. Davies, P. F. Hemodynamic shear stress and the endothelium in cardiovascular pathophysiology. Nat. Clin. Pract. Cardiovasc. Med. 6, 16-26 (2009).
106. Lam, C. F. et al. Increased blood flow causes coordinated upregulation of arterial eNOS and biosynthesis of tetrahydrobiopterin. Am. J. Physiol. Heart Circ. Physiol. 290, H786-H793 (2006).
107. Go, Y. M. et al. Protein kinase B/Akt activates c-Jun NH(2)-terminal kinase by increasing NO production in response to shear stress. J. Appl. Physiol. 91, 1574-1581 (2001).
108. Ziegler, T., Bouzourene, K., Harrison, V. J., Brunner, H. R. & Hayoz, D. Influence of oscillatory and unidirectional flow environments on the expression of endothelin and nitric oxide synthase in cultured endothelial cells. Arterioscler. Thromb. Vasc. Biol. 18, 686-692 (1998). (Pubitemid 28267646)
109. Qiu, Y. & Tarbell, J. M. Interaction between wall shear stress and circumferential strain affects endothelial cell biochemical production. J. Vasc. Res. 37, 147-157 (2000). (Pubitemid 30350883)
110. Malek, A. M., Alper, S. L. & Izumo, S. Hemodynamic shear stress and its role in atherosclerosis. JAMA 282, 2035-2042 (1999).
111. Traub, O. & Berk, B. C. Laminar shear stress: mechanisms by which endothelial cells transduce an atheroprotective force. Arterioscler. Thromb. Vasc. Biol. 18, 677-685 (1998). (Pubitemid 28267645)
112. Papadaki, M. et al. Differential regulation of protease activated receptor-1 and tissue plasminogen activator expression by shear stress in vascular smooth muscle cells. Circ. Res. 83, 1027-1034 (1998). (Pubitemid 28520932)
113. Papaharalambus, C. A. & Griendling, K. K. Basic mechanisms of oxidative stress and reactive oxygen species in cardiovascular injury. Trends Cardiovasc. Med. 17, 48-54 (2007). (Pubitemid 46205327)
114. Nakazawa, G. et al. The pathology of neoatherosclerosis in human coronary implants bare-metal and drug-eluting stents. J. Am. Coll. Cardiol. 57, 1314-1322 (2011).
115. Tabas, I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler. Thromb. Vasc. Biol. 25, 2255-2264 (2005). (Pubitemid 41552640)
116. Tulenko, T. N., Chen, M., Mason, P. E. & Mason, R. P. Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J. Lipid Res. 39, 947-956 (1998). (Pubitemid 28221998)
117. Farb, A., Shroff, S., John, M., Sweet, W. & Virmani, R. Late arterial responses (6 and 12 months) after (32)P β-emitting stent placement: sustained intimal suppression with incomplete healing. Circulation 103, 1912-1919 (2001). (Pubitemid 32328407)
118. Jeremias, A. et al. Stent thrombosis after successful sirolimus-eluting stent implantation. Circulation 109, 1930-1932 (2004). (Pubitemid 38544480)
119. Kushner, F. G. et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation 120, 2271-2306 (2009).
120. Park, S. J. et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N. Engl. J. Med. 362, 1374-1382 (2010).
121. Valgimigli, M. Assessing the most appropriate duration of dual antiplatelet therapy after coronary stenting: the PRODIGY study. Hot Line III-Acute coronary syndromes. European Society of Cardiology online, http://www.escardio.org/about/press/press-releases/esc11-paris/Pages/ HL3-PRODIGY.aspx (2011).
122. Gwon, H. C. et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the efficacy of xience/promus versus cypher to reduce late loss after stenting (EXCELLENT) randomized, multicenter study. Circulation 125, 505-513 (2012).
123. Mauri, L. et al. Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. Am. Heart J. 160, 1035-1041 (2010).